Skip to Content

Cerianna Approval History

FDA Approved: Yes (First approved May 20, 2020)
Brand name: Cerianna
Generic name: fluoroestradiol F18
Dosage form: Injection
Company: Zionexa USA
Treatment for: Diagnosis and Investigation

Cerianna (fluoroestradiol F18) is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.

Development History and FDA Approval Process for Cerianna

DateArticle
May 27, 2020Approval FDA Approves Cerianna (fluoroestradiol F18) PET Imaging Agent for Use in Patients with Recurrent or Metastatic Breast Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.